Increasing number of haemophilic patients worldwide and increased diagnosis rate across the globe to drive global haemophilia treatment market
According to TechSci Research report, “Global Haemophilia Treatment Market By Type, By Product, By Treatment, By Therapy, By Region, Competition, Forecast & Opportunities, 2025”, global haemophilia treatment market is expected to witness significant CAGR during the forecast period. Increasing number of haemophilic patients worldwide is one of the major factors accounting for the growth of global haemophilia treatment market. Moreover, upsurge in the use of prophylactic treatment for hemophilia is expected to bode well for the growth of global haemophilia treatment market through the forecast period. In addition to this, supportive initiatives plan by governments worldwide in order to commence early screening of neonates is expected to positively influence the growth of global haemophilia treatment market in the years to come. Also, growing severity with the genetic evolution, is making headway for the growth of global haemophilia treatment market. Furthermore, rising availability of hemophilia drugs is also contributing to increasing market growth. However, there are certain factors that might hamper the growth of global haemophilia treatment market over the coming years including high cost of recombinant products, stringent government regulations and serious adverse effects associated with plasma derived products.
Browse XX market data Tables and XX Figures spread through XXX Pages and an in-depth TOC on “ Global Haemophilia Treatment Market “
Global haemophilia treatment market can be segmented based on type, product, treatment, therapy, company, and region. Considering the product, the market is fragmented into plasma derived coagulation factor concentrate, recombinant coagulation factor concentrates, desmopressin, and antifibrinolytics agents. Here, the recombinant coagulation factor concentrates segment dominated the global haemophilia treatment market in terms of largest market share until 2019 and is further anticipated to maintain its dominance during the forecast period as well, which can be accredited to increase in production of recombinant factor concentrates to treat hemophilia coupled with high availability of plasma-derived concentrates. Moreover, enhanced safety of replacement therapy by using recombinant factor concentrates, is further boosting the segmental growth. In terms of treatment, the market is categorized into on-demand and prophylaxis. Out of which, the prophylaxis treatment segment is forecast to grow at a high CAGR in the years to come, on account of its efficiency and better end results. Additionally, preference for long-term prophylaxis treatment to prevent chronic arthropathy and joint bleeding in patients with severe haemophilia, is further contributing to the growth of the segment.
Novo Nordisk A/S, Shire, Chugai Pharmaceutical Co. Ltd., Bayer AG, Pfizer, Inc., CSL Behring, BioMarin, Octopharma AG, Genzyme Corporation, Spark Therapeutics, Inc., Baxter International, Inc.s, Grifols SA, Kedrion, Biogen Idec, Inc., Hospira, Incare among others are the leading players operating in global haemophilia treatment market. The players are adopting several growth strategies to enhance the market scenario of haemophilia treatment. Other competitive strategies include mergers & acquisitions; agreements, partnerships, and collaborations; and expansions to diverse their product portfolio in order to strengthen their market position.
download sample report @ https://www.techsciresearch.com/sample-report.aspx?cid=5057
customers can also request for 10% free customization on this report.
“North America is forecast to dominate the global haemophilia treatment market during the next five years on account of presence of favorable healthcare reimbursement and insurance policies in the region. Furthermore, growing demand and adoption rate of haemophilia medications is also contributing to the growing trend. Additionally, better diagnostic techniques in the region is anticipated to bolster the growth of growth of global haemophilia treatment market over the coming years.”, said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.
“Global Haemophilia Treatment Market By Type, By Product, By Treatment, By Therapy, By Region, Competition, Forecast & Opportunities, 2025” has evaluated the future growth potential of global haemophilia treatment market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in global haemophilia treatment market.
Mr. Ken Mathews
708 Third Avenue,
New York – 10017